The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Open accessThe DOI matches its Crossref record; 119 of the 140 references it cites were found in a registry or an index; 9 of the 77 sources its claims cite were checked for support.
Abstract
OBJECTIVE: The objective of the study was to develop clinical practice guidelines for the diagnosis of Cushing's syndrome. PARTICIPANTS: The Task Force included a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, five additional experts, a methodologist, and a medical writer. The Task Force received no corporate funding or remuneration. CONSENSUS PROCESS: Consensus was guided by systematic reviews of evidence and discussions. The guidelines were reviewed and approved sequentially by The Endocrine Society's CGS and Clinical Affairs Core Committee, members responding to a web posting, and The Endocrine Society Council. At each stage the Task Force incorporated needed changes in response to written comments. CONCLUSIONS: After excluding exogenous glucocorticoid use, we recommend testing for Cushing's syndrome in patients with multiple and progressive features compatible with the syndrome, particularly those with a high discriminatory value, and patients with adrenal incidentaloma. We recommend initial use of one test with high diagnostic accuracy (urine cortisol, late night salivary cortisol, 1 mg overnight or 2 mg 48-h dexamethasone suppression test). We recommend that patients with an abnormal result see an endocrinologist and undergo a second test, either one of the above or, in some cases, a serum midnight cortisol or dexamethasone-CRH test. Patients with concordant abnormal results should undergo testing for the cause of Cushing's syndrome. Patients with concordant normal results should not undergo further evaluation. We recommend additional testing in patients with discordant results, normal responses suspected of cyclic hypercortisolism, or initially normal responses who accumulate additional features over time.
Overview
CoChat Summary
TL;DR
This Endocrine Society guideline recommends case detection for Cushing's syndrome only in selected high-risk groups, initial testing with one of four high-accuracy tests, and confirmatory second testing before cause-directed evaluation. It emphasizes excluding exogenous glucocorticoids first and notes that most recommendations rest on very low- to low-quality evidence.
Key findings
- Exclude exogenous glucocorticoid exposure before biochemical testing (1QQQQ); test patients with multiple and progressive features, unusual features for age, children with decreasing height percentile and increasing weight, or adrenal incidentaloma compatible with adenoma, and recommend against widespread testing in other groups.
- Initial testing should use one of: urine free cortisol (at least two measurements), late-night salivary cortisol (two measurements), 1-mg overnight dexamethasone suppression test, or 48-h 2 mg/d dexamethasone suppression test; recommend against random serum cortisol/plasma ACTH, urinary 17-ketosteroids, insulin tolerance test, loperamide test, and cause-directed tests for initial diagnosis.
- Reported test performance includes late-night salivary cortisol sensitivity 92–100% and specificity 93–100%; pediatric UFC sensitivity about 89%; 1-mg DST at a 1.8 µg/dL cutoff sensitivity >95% with specificity 80%, rising to >95% specificity at a 5 µg/dL threshold; LDDST sensitivity 96% and specificity 70%; dexamethasone-CRH sensitivity 98% and specificity 60%.
- Special-population recommendations: use UFC and avoid dexamethasone testing in pregnancy; avoid dexamethasone testing with enzyme-inducing antiepileptics; suggest 1-mg overnight DST rather than UFC in severe renal failure; suggest UFC or midnight salivary cortisol rather than DSTs in suspected cyclic Cushing's; suggest 1-mg DST or late-night cortisol rather than UFC in adrenal incidentaloma.
Methods
- A six-member Task Force appointed by The Endocrine Society's Clinical Guidelines Subcommittee, including a chair, five additional experts, a methodologist, and a medical writer, received no corporate funding or remuneration; consensus was guided by systematic reviews and discussions and approved sequentially by Society bodies and members.
- Recommendations used the GRADE approach: strong recommendations phrased “we recommend” with number 1, weak recommendations “we suggest” with number 2; evidence quality ranged from QEEE (very low) to QQQQ (high), informed by best available research evidence and systematic reviews/meta-analyses of test accuracy.
- The guideline presents evidence, values, and remarks linked to each recommendation; technical remarks often reflect the panel's unsystematic observations applied to a typical patient.
Limitations
- Stated: the majority of recommendations are based on very low- to low-quality evidence, with limited data linking diagnostic strategies to patient-important outcomes and no higher-quality direct evidence available.
- Stated: published data often come from larger tertiary referral centers and may be biased toward more diagnostically challenging cases, higher pretest probability, and greater disease severity, potentially giving an overly sanguine view of test performance in unselected populations.
- Evident from the text: this is a consensus guideline rather than a primary study, and some technical recommendations rest on unsystematic panel observations; data on treating mild/subclinical Cushing's syndrome and adrenal incidentaloma are described as limited and conflicting.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 4 Not valid · 37 Not checked · 33 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Another study of 86 consecutive obese subjects referred to an endocrine clinic with diabetes mellitus, hypertension, and/or the polycystic ovary syndrome found a 5.8% incidence of Cushing's syndrome (35).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.3 Evidence
What the sources say
- Partly supportedcites [35] 35. Ness-Abramof R, Nabriski D, Apovian CM, Niven M, Weiss E, Shapiro MS, Shenkman L 2002 Overnight dexamethasone suppression test: a reliable screen for Cushing's syndrome in the obese. Obes Res 10:1217-1221 sourceExperimental — accuracy not yet measured
The Patients section describes 86 obese patients referred to an endocrine clinic, and the Results report five Cushing’s syndrome diagnoses—5/86, or approximately 5.8%, though the paper prints 5.7%. The copy does not say the patients were consecutive. It also reports that 51 had obesity alone, so diabetes, hypertension, and polycystic ovary disease do not describe the whole group. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The salivary glands express 11-hydroxysteroid dehydrogenase type 2 (11-HSD2), which converts the biologically active cortisol to inactive cortisone (75).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Remarks for late-night salivary cortisol
What the sources say
- Supportedcites [75] 75. Smith RE, Maguire JA, Stein-Oakley AN, Sasano H, Takahashi K, Fuku- shima K, Krozowski ZS 1996 Localization of 11-hydroxysteroid dehydro- genase type II in human epithelial tissues. J Clin Endocrinol Metab 81:3244 - 3248 source
The paper reports 11β-HSD2 in the ducts of human parotid and submandibular salivary glands (Abstract; Discussion, p. 3247). It describes the enzyme as inactivating glucocorticoids and discusses salivary cortisol-to-cortisone ratios (Introduction; Discussion, p. 3247), supporting the stated function. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Overall, the evidence in adults suggests that the accuracy of this test is similar to that of UFC (2).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Evidence for late-night salivary cortisol
What the sources say
- Supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 source
Table 3 (Conclusions; page unavailable) reports broadly similar pooled diagnostic likelihood ratios for midnight salivary cortisol and UFC. The Summary of findings notes that evidence for salivary cortisol is more limited, consistent with the citing sentence’s cautious wording. (LLM, conf=0.88)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“When the assay upper limit of normal is used as a criterion, the overall evidence supports the diagnostic accuracy of UFC in adults suspected of having Cushing's syndrome (2,51).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.1 Evidence for use of UFC
What the sources say
- Partly supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 sourceExperimental — accuracy not yet measured
The Summary of findings says UFC has substantial evidence supporting its use to detect Cushing’s syndrome, and the pooled results table reports diagnostic accuracy across 14 UFC studies. The Subgroup analyses section identifies an assay-upper-limit cutoff, but the reported UFC estimate is pooled across studies rather than shown specifically for that cutoff. The Conclusions also limit the apparent accuracy to referral practices enriched with patients with Cushing’s syndrome; performance in usual clinical practice remains unclear. Page numbers were not available in our copy. (LLM, conf=0.83)
- Supportedcites [51] 51. Pecori Giraldi F, Ambrogio AG, De Martin M, Fatti LM, Scacchi M, Cav- agnini F 2007 Specificity of first-line tests for the diagnosis of Cushing's syndrome: assessment in a large series. J Clin Endocrinol Metab 92:4123- 4129 source
The UFC results (p. 2) report 91.2% specificity in Cushing’s syndrome suspects when values above the assay’s reference range were considered abnormal. The Discussion (p. 5) identifies that threshold as the assay’s upper limit of normal and describes UFC as having superior diagnostic performance. The study assessed specificity, rather than diagnostic accuracy across all measures. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The four recommended tests have acceptable diagnostic accuracy when the suggested cutoff points are used (2,30).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4 Evidence
What the sources say
- Partly supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 sourceExperimental — accuracy not yet measured
The Conclusions state that commonly used tests appear highly accurate in referral practices with samples enriched for Cushing’s syndrome, but that their performance in usual clinical practice is unclear. The Data extraction section says the review used cutoffs chosen by the primary studies, selecting those with the best performance when several were available; it does not establish accuracy specifically at the suggested cutoff points. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [30] 30. Batista DL, Riar J, Keil M, Stratakis CA 2007 Diagnostic tests for children who are referred for the investigation of Cushing syndrome. Pediatrics 120: e575-e586 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
48 more claims · 3 with their cited sources checked
Create a free account to see all 82 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 12
- It may state two separate claims as one. 20
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early diagnosis of secondary hypertension and the institution of appropriate targeted treatment have the potential to cure hypertension in some patients or improve BP control/reduce the number of prescribed antihypertensive medications in others.”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [118]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, accurate serum cortisol measurement is essential for the correct diagnosis and management of adrenal pathologies.”
From Serum cortisol: an up-to-date assessment of routine assay performance (2016) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the reliability of almost all markers of HPA axis activity, particularly ACTH and 24-h urinary free cortisol (UFC), is low (3,14,23)”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, UFC should not be considered an adequate screening test for SH and should be used in combination with other tests or in specific populations (1,14).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“some authors have proposed higher (3 or 8 mg) dexamethasone doses (40,46,54,56), which however did not show a better performance (14,23,66).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measured
27 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“biochemical hypercortisolism is present in a large fraction (up to 10%).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“Libe et al. (32) reported 18%; Terzolo et al. (21) quoted 5-20%, depending on referral bias and diagnostic tests and criteria.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > Subsequent evaluation
“3.9.1 We suggest the additional use of the dexamethasone-CRH test or the midnight serum cortisol test in specific situations (Fig. 1, 1QEEE).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > METHOD OF DEVELOPMENT OF EVIDENCE-BASED RECOMMENDATIONS
“strong recommendations use the phrase "we recommend" and the number 1, and weak recommendations use the phrase "we suggest" and the number 2.”
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“with expertise in development and implementation of evidencebased guidelines (1).”
BackgroundCushing, H. (1964) · Journal of Neurosurgery · doi:10.3171/jns.1964.21.4.0318 · Cited by 851 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundThe Diagnosis and Differential Diagnosis of Cushing’s Syndrome and Pseudo-Cushing’s States
Newell-Price, J., Trainer, P., Besser, M., & Grossman, A. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0346 · Cited by 833
Self-citationGold, P. W., Loriaux, D. L., Roy, A., Kling, M. A., Calabrese, J. R., Kellner, C. H., Nieman, L. K., Post, R. M., Pickar, D., Gallucci, W., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198605223142101 · Cited by 766
Self-citationThe natural history of cushing's syndrome
Plotz, C. M., Knowlton, A. I., & Ragan, C. (1952) · The American Journal of Medicine · doi:10.1016/0002-9343(52)90027-2 · Cited by 763 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundTESTS OF PITUITARY-ADRENAL SUPPRESSIBILITY IN THE DIAGNOSIS OF CUSHING'S SYNDROME*
LIDDLE, G. W. (1960) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-20-12-1539 · Cited by 735
Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease
Wei, L., MacDonald, T. M., & Walker, B. R. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00007 · Cited by 730 · cited 1×
“These data are consistent with the increased cardiovascular mortality and morbidity reported in patients with iatrogenic Cushing’s syndrome secondary to the chronic use of synthetic corticosteroids (15).”
ResultMeasurements of Serum Free Cortisol in Critically Ill Patients
Hamrahian, A. H., Oseni, T. S., & Arafah, B. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa020266 · Cited by 726 · cited 1×
“are associated with decreased serum cortisol values (39, 46).”
BackgroundMorbidity and mortality in Cushing's disease: an epidemiological approach.
Etxabe, J., & Vazquez, J. A. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02486.x · Cited by 622 · cited 2×
“0-fold, compared with the general population (4, 5).”
BackgroundIncidence and Late Prognosis of Cushing’s Syndrome: A Population-Based Study1
Lindholm, J., Juul, S., Jørgensen, J. O. L., Astrup, J., Bjerre, P., Feldt-Rasmussen, U., Hagen, C., Jørgensen, J., Kosteljanetz, M., Kristensen, L. Ø., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7093 · Cited by 619 · cited 6×
“Because some patients with Cushing’s disease demonstrate suppressibility to dexamethasone, use of this diagnostic criterion J Clin Endocrinol Metab, May 2008, 93(5):1526–1540 jcem.”
BackgroundInfluential
Cited by
Items 1,001–1,100 of 2,716
Successful treatment of Cushing’s disease caused by ectopic intracavernous microadenoma
Koizumi, M., Usui, T., Yamada, S., et al. (2008) · Pituitary · doi:10.1007/s11102-008-0156-9 · Cited by 15
“Guidelines for diagnosing Cushing’s syndrome were recently published [1].”
BackgroundPathophysiology, Diagnosis, and Treatment of Mineralocorticoid Disorders
Magill, S. B. (2014) · Comprehensive physiology · doi:10.1002/cphy.c130042 · Cited by 17
“If the test is abnormal, follow-up testing to exclude false positive results should be performed (240,422).”
Novel methods in adrenal research: a metabolomics approach
Papathomas, T. G., Sun, N., Chortis, V., Taylor, A. E., Arlt, W., Richter, S., Eisenhofer, G., Ruiz-Babot, G., Guasti, L., & Walch, A. K. (2019) · Histochemistry and Cell Biology · doi:10.1007/s00418-019-01772-w · Cited by 14
Akirov, A., Fleseriu, M., Masri‐Iraqi, H., Shochat, T., Kushnir, S., Shimon, I., & Rudman, Y. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf059 · Cited by 22
Nishijo, N., Hayama, T., Tomita, R., & Fujioka, T. (2021) · Journal of Chromatography B · doi:10.1016/j.jchromb.2021.122828 · Cited by 14
Glucocorticoid-induced Fingerprints on Visceral Adipose Tissue Transcriptome and Epigenome
García-Eguren, G., González-Ramírez, M., Vizán, P., Giró, O., Vega‐Beyhart, A., Boswell, L., Mora, M., Halperín, I., Carmona, F., Gràcia, M., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab662 · Cited by 16
Whole blood methylome-derived features to discriminate endocrine hypertension
Armignacco, R., Reel, P. S., Reel, S., Jouinot, A., Septier, A., Gaspar, C., Perlemoine, K., Larsen, C. K., Bouys, L., Braun, L., et al. (2022) · Clinical Epigenetics · doi:10.1186/s13148-022-01347-y · Cited by 18
Boro, H., Mannar, V., Malhotra, R., Alam, S., Khatiwada, S., Kubihal, S., Dogra, V., Golla, K. K., Mathew, U. E., Halebidu, T., et al. (2023) · Clinical Endocrinology · doi:10.1111/cen.14944 · Cited by 16
“A value ≥50 nmol/L was considered a non‐suppressed LDDST.(26) High‐dose dexamethasone suppression test (HDDST) was done by administering 2 mg dexamethasone every 6 h for 48 h followed by measurement of serum cortisol at 0900 h, 6 h after the last dose.”
MethodInfluentialAdrenal Cushing’s syndrome in children
Guarnotta, V., Emanuele, F., Salzillo, R., & Giordano, C. S. D. S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1329082 · Cited by 17
Presentation and management of patients with adrenal masses: a large tertiary centre experience
Suntornlohanakul, O., Mandal, S., Saha, P., Saygılı, E. S., Asia, M. F., Arlt, W., Elhassan, Y., Prete, A., & Ronchi, C. L. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae131 · Cited by 16
Emerging drugs for Cushing’s disease
Guelho, D., & Grossman, A. B. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1047762 · Cited by 14
“Excess secretion of ACTH augments cortisol production by the adrenal gland, disturbing the normal cortisol feedback mechanism of the hypothalamo-pituitary-adrenal (HPA) axis, with loss of the circadian rhythm and excess cortisol secretion [2].”
BackgroundPredictors of long-term remission after transsphenoidal surgery in Cushing's disease
Galiana, P. A., Fajardo, C., Suárez, P. A. R., Gómez-Vela, J., Escrivá, C., & Rovira-Lillo, V. (2013) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2013.10.002 · Cited by 17
Evaluation of salivary cortisol measurements for the diagnosis of subclinical Cushing’s syndrome
Tateishi, Y., Kouyama, R., Mihara, M., Doi, M., Yoshimoto, T., & Hirata, Y. (2012) · Endocrine Journal · doi:10.1507/endocrj.ej11-0204 · Cited by 15
The dynamics of a serum steroid profile after stimulation with intravenous ACTH
Lindner, J. M., Suhr, A. C., Grimm, S., Möhnle, P., Vogeser, M., & Briegel, J. (2017) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2017.12.045 · Cited by 13
Babińska, A., Kaszubowski, M. F., Kmieć, P., & Sworczak, K. (2018) · Steroids · doi:10.1016/j.steroids.2018.08.011 · Cited by 15
de Graaf, A. J., Mulder, A. L., & Krabbe, J. G. (2019) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563219870834 · Cited by 14
“non-suppressed) DSTs is the use of exogenous oestrogens, which increase cortisol-binding globulin and therefore total s-CORT (but not the free fraction).(1) It has long been known that false-positives can also occur due to insufficient serum concentrations of dexamethasone (s-DXM), e.”
InfluentialFunctional imaging in ectopic Cushing syndrome
Grigoryan, S., Avram, A. M., & Turcu, A. F. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000541 · Cited by 18
“Planar scintigraphy with singlephoton emission computed tomography (SPECT) using [(111)In]-DTPA-octreotide (pentetreotide), a SSR ligand, have been used for detection of neuroendocrine tumors since the 1980s, but their overall sensitivity is modest [32].”
MethodPituitary-adrenal axis and peripheral cortisol metabolism in obese patients
Ceccato, F., Lizzul, L., Barbot, M., & Scaroni, C. M. (2020) · Endocrine · doi:10.1007/s12020-020-02392-4 · Cited by 21
Kong, S. H., Kim, J. H., & Shin, C. S. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0301 · Cited by 17
Updates in the outcomes of radiation therapy for Cushing’s disease
Gheorghiu, M. L. (2021) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2021.101514 · Cited by 16
Tumor Shrinkage by Metyrapone in Cushing Disease Exhibiting Glucocorticoid-Induced Positive Feedback
Tsujimoto, Y., Shichi, H., Fukuoka, H., Yamamoto, M., Sato, I., Imanishi, T., Nakamura, T., Inoshita, N., Ishida, A., Yamada, S., et al. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab055 · Cited by 15
“Glucocorticoid (GC) resistance against a small Dex dose has been elucidated by the presence of a higher threshold in CD, since adrenocorticotropic hormone (ACTH) secretion has been found to be suppressed by a larger dose of Dex in the majority of CD cases [1, 2].”
BackgroundMethodAkirov, A., Shimon, I., Fleseriu, M., Dotan, I., Manisterski, Y., Aviran-Barak, N., Nadler, V., Alboim, S., Shochat, T., Tsvetov, G., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11061558 · Cited by 16
“The computerized database of the HMO was screened for all individuals who fulfilled the following criteria: • The recorded biochemical data were compatible with a CD diagnosis as stipulated in the Endocrine Society Clinical Guidelines [11].”
MethodPituitary tumor centers of excellence for Cushing’s disease
Couselo, M., Frara, S., Giustina, A., & Casanueva, F. F. (2022) · Pituitary · doi:10.1007/s11102-022-01264-6 · Cited by 14
“When signs and symptoms of the patient suggest a Cushing’s disease, he first step is to demonstrate the presence of chronic hypercortisolism and then ACTH-dependent, which needs to be performed through biochemical tests [5, 6].”
BackgroundAntonini, S. R. R., Leal, L. F., & Cavalcanti, M. M. (2014) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2014.941813 · Cited by 16
“In such conditions, 1 mg DST is preferable to UFC and LNSF [42].”
BackgroundSalivary cortisol or cortisone?
Raff, H., & Findling, J. W. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.192 · Cited by 14
Self-citationBudget impact of using midnight salivary cortisol in the diagnosis of hypercortisolism
León-Justel, A., Mangas, M. A., Fontán, R. I., Luque, J. C., Moreno, E. V., Atutxa, A. M., del Rey, T. H., Martin-Rodriguez, J. F., Soto-Moreno, A., & Leal-Cerro, A. (2011) · Clinica Chimica Acta · doi:10.1016/j.cca.2011.08.013 · Cited by 14
Ghazi, A. A., Dezfooli, A. A., Amirbaigloo, A., Kakhki, A. D., Mohammadi, F., Tirgari, F., & Pourafkari, M. (2015) · Endokrynologia Polska · doi:10.5603/ep.2015.0002 · Cited by 14
“(8 mg daily for two days) suppression tests, except that instead of measuring urinary ketosteroids, UFC was measured [15–17].”
MethodTestosterone replacement therapy: role of pituitary and thyroid in diagnosis and treatment
Crawford, M., & Kennedy, L. (2016) · Translational Andrology and Urology · doi:10.21037/tau.2016.09.01 · Cited by 17
“If Cushing syndrome is suspected screening should involve one or more of the following, depending on the level of suspicion: overnight 1 mg dexamethasone suppression test, midnight salivary cortisol on two consecutive nights, and/or 24 hour urine free cortisol measurement on two separate occasions (50).”
MethodSasaki, Y., Katabami, T., Asai, S., Fukuda, H., & Tanaka, Y. (2017) · Endocrine Journal · doi:10.1507/endocrj.ej17-0083 · Cited by 14
Daimon, M., KAMBA, A., Murakami, H., Mizushiri, S., Osonoi, S., Matsuki, K., Sato, E., Tanabe, J., Takayasu, S., Matsuhashi, Y., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-10815-y · Cited by 16
The Utility of Preoperative ACTH/Cortisol Ratio for the Diagnosis and Prognosis of Cushing's Disease
Selek, A., Çetinarslan, B., Cantürk, Z., Tarkun, İ., Akyay, Ö. Z., Çabuk, B., & Ceylan, S. (2018) · Journal of Neurosciences in Rural Practice · doi:10.4103/jnrp.jnrp_308_17 · Cited by 15
“Loss of negative cortisol feedback at the pituitary level is a key feature of CD and represents the main mechanism of the diagnostic tests.[1] Normally, administration of an exogenous glucocorticoid leads to suppression of endogenous cortisol and ACTH production, whereas in CD, there is inadequate suppression.”
BackgroundResultInfluentialAntonelli, G., Sciacovelli, L., Aita, A., Padoan, A., & Plebani, M. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.07.005 · Cited by 15
Autonomous hypercortisolism: definition and clinical implications
Reimondo, G., Puglisi, S., Pia, A. R., & Terzolo, M. (2018) · Minerva Endocrinology · doi:10.23736/s0391-1977.18.02884-5 · Cited by 16
When to Intervene for Subclinical Cushing's Syndrome
Hsieh, L. B., MacKinney, E. C., & Wang, T. S. (2019) · Surgical Clinics of North America · doi:10.1016/j.suc.2019.04.011 · Cited by 17
Diagnostic Accuracy of the Aldosterone–to–Active Renin Ratio for Detecting Primary Aldosteronism
Pilz, S., Keppel, M. H., Trummer, C., Theiler‐Schwetz, V., Pandis, M., Borzan, V., Pittrof, M., Obermayer-Pietsch, B. M., Grübler, M. R., Verheyen, N., et al. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00145 · Cited by 16
“In addition, two patients were diagnosed with pheochromocytoma on the basis of elevated plasma metanephrines and/or normetanephrines and two were diagnosed with hypercortisolism [26, 27].”
BackgroundThe characteristics of captopril challenge test–positive patients using various criteria
Kidoguchi, S., Sugano, N., Hayashi-Ishikawa, N., Morisawa, N., Tokudome, G., & Yokoo, T. (2019) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320319870891 · Cited by 16
Markers of Subclinical Cardiovascular Disease in Patients with Adrenal Incidentaloma
Szychlińska, M., Baranowska-Jurkun, A., Matuszewski, W., Wołos-Kłosowicz, K., & Bandurska-Stankiewicz, E. M. (2020) · Medicina · doi:10.3390/medicina56020069 · Cited by 18
Ladwig, K., Schriever, S. C., Atasoy, S., Bidlingmaier, M., Kruse, J., & Johar, H. (2020) · Scientific Reports · doi:10.1038/s41598-020-71204-6 · Cited by 14
Huayllas, M. K. P., Smith, L. M., Gallagher, J. C., Netzel, B. C., Singh, R. J., & Kater, C. E. (2021) · Clinical Endocrinology · doi:10.1111/cen.14445 · Cited by 14
Kline, G. A., So, B., Campbell, D. J. T., Chin, A., Harvey, A. M., Venos, E., Pasieka, J. L., & Leung, A. A. C. (2021) · Clinical Endocrinology · doi:10.1111/cen.14546 · Cited by 16
Bariatric surgery for obesity and hidden Cushing syndrome
Savastano, S., Pivonello, R., & Colao, A. (2008) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2008.07.006 · Cited by 14
Österreichischer Blutdruckkonsens 2019
Hypertensiologie, Ö. G. F., Weber, T., Atherosklerosegesellschaft, Ö., Gesellschaft, Ö. D., Angiologie, Ö. G. F. I., Nephrologie, Ö. G. F., Gesellschaft, Ö. K., Neurologie, Ö. G. F., Schlaganfall-Gesellschaft, Ö., Allgemeinmedizin, Ö. G. F., et al. (2019) · Wiener klinische Wochenschrift · doi:10.1007/s00508-019-01565-0 · Cited by 18
[A critical analysis of cortisol measurements: an update].
Maidana, P. N. A., Bruno, O. D., & Mesch, V. (2013) · PubMed · Cited by 45
Hinojosa-Amaya, J. M., González-Colmenero, F. D., Alvarez-Villalobos, N. A., Salcido-Montenegro, A., Quintanilla-Sánchez, C., Moreno-Peña, P. J., Manzanares-Gallegos, D. M., Gutiérrez-Dávila, L. F., Castillo-Morales, P. L., García-Campa, M., et al. (2024) · Pituitary · doi:10.1007/s11102-024-01408-w · Cited by 14
A commentary on diagnosing Cushing’s disease in the context of renal failure
Raff, H., Cohen, E. P., & Findling, J. W. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0560 · Cited by 13
Self-citationBerndt, V., Dahlqvist, P., de Verdier, J., Ryberg, H., & Ragnarsson, O. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1028804 · Cited by 15
Fatty Liver Disease Along Cushing Syndrome Evolution
Marengo, M., Briet, C., Munier, M., Boursier, J., Rodien, P., & Suteau, V. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae568 · Cited by 16
Current strategies for the treatment of severe Cushing’s syndrome
Alexandraki, K., & Grossman, A. B. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2016.1123615 · Cited by 14
Li, S., Yang, C., Fan, J., Yao, Y., Lv, X., Guo, Y., & Zhang, S. (2020) · BMC Endocrine Disorders · doi:10.1186/s12902-020-0539-0 · Cited by 13
Attri, B., Goyal, A., Kalaivani, M., Kandasamy, D., Gupta, Y., Agarwal, S., Shamim, S. A., Damle, N., Dhingra, A., Jyotsna, V. P., et al. (2023) · Endocrine · doi:10.1007/s12020-022-03298-z · Cited by 15
“Endogenous CS was diagnosed according to Endocrine Society guidelines [16], as detailed in supplementary material (Appendix S1).”
MethodImpact of Variation between Assays and Reference Intervals in the Diagnosis of Endocrine Disorders
Lorde, N., Elgharably, A., & Kalaria, T. (2023) · Diagnostics · doi:10.3390/diagnostics13223453 · Cited by 18
Castro, M. A., Torre, E. L. M., Lozano-Aida, C., García-Centeno, R., Fernández, L. G., Idrobo, C., Achote, E., Irigaray, A., Rodríguez, M. D. M., Paja, M., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf252 · Cited by 14
Trementino, L., Zilio, M., Marcelli, G., Michetti, G., Barbot, M., Ceccato, F., Boscaro, M., Scaroni, C. M., & Arnaldi, G. (2014) · Endocrine · doi:10.1007/s12020-014-0499-0 · Cited by 13
Seidel, E., & Scholl, U. I. (2016) · Frontiers in Endocrinology · doi:10.3389/fendo.2016.00075 · Cited by 16
Incidence of Cushing’s syndrome in patients with significant hypercortisoluria
Hirsch, D., Tsvetov, G., Manisterski, Y., Aviran-Barak, N., Nadler, V., Alboim, S., & Kopel, V. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0631 · Cited by 15
Genetic and epigenetic analyses of aldosterone-producing adenoma with hypercortisolemia
Kometani, M., Yoneda, T., Demura, M., Aono, D., Gondoh, Y., Karashima, S., Nishimoto, K., Yasuda, M., Horike, S., & Takeda, Y. (2019) · Steroids · doi:10.1016/j.steroids.2019.108470 · Cited by 15
Великанова, Л. И., Ривгатовна, Ш. З., Ворохобина, Н. В., & Валерьевна, М. Е. (2019) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-019-04597-8 · Cited by 12
Molecular skin changes in Cushing syndrome and the effects of treatment
Karaca, Z., Taheri, S., Fırat, S. T., Borlu, M., Zararsız, G., Mehmetbeyoğlu, E., Çağlar, A. S., Hacıoğlu, A., Tanrıverdi, F., Unluhizarci, K., et al. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01285-7 · Cited by 13
Wu, Y., Cai, Y., Rui, W., Tang, Y., Yang, Z., He, M., Ye, H., Wang, Y.-F., Zhao, Y., Ma, Z.-Y., et al. (2021) · Clinical Endocrinology · doi:10.1111/cen.14574 · Cited by 11
“Cushing disease is associated with central obesity, cardiovascular disease, osteoporosis and metabolic syndrome.(2,3) It is a severe and potentially fatal disease and among the most challenging endocrine disorders to diagnose and treat.”
BackgroundMallari, R. J., Thakur, J. D., Barkhoudarian, G., Eisenberg, A., Rodriguez, A., Rettinger, S. R., Cohan, P., Nieman, L. K., & Kelly, D. F. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab659 · Cited by 14
Self-citationViecceli, C., Mattos, A. C. V., Hirakata, V. N., Garcia, S. P., Rodrigues, T. D. C., & Czepielewski, M. A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1145775 · Cited by 35
“7 times higher than the general population (3, 4).”
BackgroundThe 4‐mg intravenous dexamethasone suppression test in the diagnosis of Cushing’s syndrome
Jung, C., ALFORD, F. P., Topliss, D. J., Burgess, J. R., Long, F., Gome, J. J., Stockigt, J., & Inder, W. J. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03756.x · Cited by 15
Mass spectrometric quantification of salivary metanephrines—A study in healthy subjects
Osinga, T. E., van der Horst‐Schrivers, A. N. A., van Faassen, M. H. J. R., Kerstens, M. N., Dullaart, R. P. F., Pacák, K., Links, T. P., & Kema, I. P. (2016) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2016.02.003 · Cited by 16
How to Escape from Primary Aldosteronism? News and Views on an Adrenal Disorder of Salt Retention
Willenberg, H. S. (2017) · Hormone and Metabolic Research · doi:10.1055/s-0043-100767 · Cited by 14
“While cortisol co-secretion is rare in patients with small aldosteronomas [3, 87] patients with PA and relatively large adrenal tumors ( > 2 cm) or clinical signs of hypercortisolism [47] should undergo specific screening [48, 49].”
BackgroundNew and emerging drug therapies for Cushing’s disease
Störmann, S., & Schopohl, J. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1504021 · Cited by 18
Secretory tumors of the pituitary gland: a clinical biochemistry perspective
Gounden, V., Rampursat, Y., & Jialal, I. (2018) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2018-0552 · Cited by 15
Minimally invasive approach to the adrenal gland in obese patients with Cushing’s syndrome
Ortenzi, M., Balla, A., Ghiselli, R., Vergari, R., Silecchia, G., Guerrieri, E., Paganini, A. M., & Guerrieri, M. (2019) · Minimally Invasive Therapy & Allied Technologies · doi:10.1080/13645706.2018.1536669 · Cited by 13
Clinical utility of an ultrasensitive urinary free cortisol assay by tandem mass spectrometry
Luo, A., Elgierari, E. M., Nally, L. M., Sturmer, L. R., Dodd, D., & Shi, R. (2019) · Steroids · doi:10.1016/j.steroids.2019.03.014 · Cited by 13
“UFC test is an important first-line screening test in patients with suspected CS [4,6].”
Ohno, Y., Sone, M., Inagaki, N., Takeda, Y., Kurihara, I., Tsuiki, M., Ichijo, T., Wada, N., Katabami, T., Ogawa, Y., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02790 · Cited by 16
Ambrus, L., & Westling, S. (2019) · Neuropsychobiology · doi:10.1159/000500737 · Cited by 16
Nikbakht, R., Zargar, M., Moramezi, F., Ziafat, M., Tabesh, H., Sattari, A. R., & Sattari, S. A. (2020) · Hormone and Metabolic Research · doi:10.1055/a-1079-5342 · Cited by 13
“Exclusion criteria were patients with PCOS diagnosis based on Rotterdam criteria [11], previous ovary surgery, ovarian insufficiency, endometriosis, some medical conditions like (diabetes mellitus, thyroid dysfunction, hyperprolactinemia, Cushing’s syndrome [12]), being smoker and use of the drugs like spironolactone,…”
BackgroundRadiologically defined lipid-poor adrenal adenomas: histopathological characteristics
Leo, A. D., Mosconi, C., Zavatta, G., Tucci, L., Nanni, C., Selva, S., Balacchi, C., Ceccarelli, C., Santini, D., Pantaleo, M. A., et al. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01198-5 · Cited by 13
Endocrine Testing Protocols: Hypothalamic Pituitary Adrenal Axis
J.Yeo, K.-T., Babić, N., Hannoush, Z. C., & Weiss, R. E. (2014) · MDText.com, Inc. eBooks · Cited by 13
Adrenocortical Adenoma and Central Serous Chorioretinopathy: A Rare Association?
Pastor‐Idoate, S., Peña, D., & Herreras, J. M. (2011) · Case Reports in Ophthalmology · doi:10.1159/000333556 · Cited by 13
Belaya, Z. E., Ильин, А. В., Melnichenko, G. A., Rozhinskaya, L. Y., Dragunova, N. V., Dzeranova, L. K., Ogneva, N. A., Бутрова, С. А., Troshina, E. A., Kolesnikova, G. S., et al. (2011) · Obesity and metabolism · doi:10.14341/2071-8713-4954 · Cited by 16
Endoscopic transsphenoidal pituitary surgery
Hofstetter, C. P., Anand, V. K., & Schwartz, T. H. (2011) · Operative Techniques in Otolaryngology-Head and Neck Surgery · doi:10.1016/j.otot.2011.09.002 · Cited by 13
Čerina, V., Kruljac, I., Radošević, J. M., Kirigin, L. S., Stipić, D., Pećina, H. I., & Vrkljan, M. (2016) · Medicine · doi:10.1097/md.0000000000002898 · Cited by 15
“Microprolactinomas were diagnosed in patients with adenomas <10 mm and serum prolactin (PRL) levels >70 mg/L, and macroprolactinomas in patients with adenomas >10 mm and serum PRL >100 mg/L.11 Somatotropinomas were diagnosed in patients with increased age-adjusted IGF-I concentrations and GH >0.5 ng/mL during the oral…”
BackgroundInfluentialFan, Y., Li, D., Liu, Y., Feng, M., Chen, Q., & Wang, R. (2020) · International Journal of Machine Learning and Cybernetics · doi:10.1007/s13042-020-01192-6 · Cited by 14
Biochemical Testing for Neuroendocrine Tumors
Vinik, A. I., & Silva, M. P. (2009) · Springer eBooks · doi:10.1007/978-1-4419-1069-1_26 · Cited by 14
Bedtime Salivary Cortisol as a Screening Test for Cushing Syndrome in Children
Ueland, G. Å., Kellmann, R., Jørstad Davidsen, M., Viste, K., Husebye, E. S., Almås, B., Storr, H. L., Sagen, J. V., Mellgren, G., Júlíusson, P. B., et al. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab033 · Cited by 12
“Late-night salivary cortisol measurement is established as a valid screening test for CS in adults [11].”
BackgroundMethodInfluentialSleep disruption in patients with active and treated endogenous Cushing’s syndrome
Geer, E. B., Grillo, I., Li, Q., Robins, H., Cohen, V. V., Baratz, H. Q., Garcia, C., Sazo, M., Lin, A. L., Cohen, M. A., et al. (2024) · Pituitary · doi:10.1007/s11102-024-01450-8 · Cited by 15
“A defining feature of CS is absence of the HPA axis circadian rhythm, which is normally characterized by high circulating cortisol levels in the early morning, with decreases in the afternoon and evening, reaching a nadir around midnight [14].”
BackgroundInfluentialVarlamov, E. V., Park, B., & Fleseriu, M. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf552 · Cited by 18
Recommendations for the diagnosis and radiological follow-up of pituitary neuroendocrine tumours
Fajardo, C., Villar, R., Gómez‐Ansón, B., Brea, B., Mosqueira, A. J., Mollá, E., Enseñat, J., Riesgo, P., Arboniés, J. C., & Hernando, O. (2022) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2021.10.014 · Cited by 15
Valassi, E., Manichanh, C., Amodru, V., Fernández, P. G., Gaztambide, S., Yáñez, F., Martel‐Duguech, L., Puig‐Domingo, M., & Webb, S. M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1074757 · Cited by 16
Paediatric Cushing syndrome: a prospective cohort study
Tatsi, C., Kamilaris, C. D. C., Keil, M. F., Saidkhodjaeva, L., Faucz, F. R., Chittiboina, P., & Stratakis, C. A. (2023) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(23)00264-x · Cited by 23
Fukumoto, T., Umakoshi, H., Iwahashi, N., Ogasawara, T., Yokomoto‐Umakoshi, M., Kaneko, H., Fujita, M., Uchida, N., Nakao, H., Kawamura, N., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105087 · Cited by 16
Magnesium, selenium and zinc deficiency compromises antioxidant defense in women with obesity
de Oliveira, A. R. S., Cruz, K. J. C., Morais, J. B. S., dos Santos, L. R., Melo, S. R. D. S., Fontenelle, L. C., Severo, J. S., Beserra, J. B., de Sousa, T. G. V., de Freitas, S. T., et al. (2024) · BioMetals · doi:10.1007/s10534-024-00625-x · Cited by 15
“The determination of the plasma leptin concentration was carried out using the radioimmunoassay method with the Elisa kit (Nieman et al. 2008).”
Diagnosis and management of pituitary adenomas in children and adolescents
Maiter, D. M., Chanson, P., Constantinescu, S. M., & Linglart, A. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae120 · Cited by 20
Cushing's syndrome of nonpituitary causes
Carroll, T. B., & Findling, J. W. (2009) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32832d8950 · Cited by 15
Self-citationMathioudakis, N. N., Sundaresh, R., Giantini-Larsen, A., Ruff, W. E., Schiller, J., Guerrero‐Cazares, H., Burger, P. C., Salvatori, R., & Quiñones‐Hinojosa, A. (2014) · Pituitary · doi:10.1007/s11102-014-0553-1 · Cited by 12
Utility of a Single Late-Night Plasma Cortisol and Acth for the Diagnosis of Cushing Syndrome
Jarial, K. D. S., Bhansali, A. K., Mukherjee, K. K., Pal, R., Sharma, A. D., Vashishtha, R. K., Sukumar, S. P., Sachdeva, N. K., & Walia, R. (2017) · Endocrine Practice · doi:10.4158/ep171803.or · Cited by 12
Abe, I., Sugimoto, K., Miyajima, T., Ide, T., Minezaki, M., Takeshita, K., Takahara, S., Nakagawa, M., Fujimura, Y., Kudo, T., et al. (2018) · Internal Medicine · doi:10.2169/internalmedicine.0550-17 · Cited by 14
“provided patients have both a low morning ACTH level (<10 pg/mL) and loss of diurnal serum cortisol rhythm (10, 11, 16).”
BackgroundFoster, T. R., Bancos, I., McKenzie, T. J., Dy, B. M., Thompson, G. B., & Lyden, M. L. (2020) · Surgery · doi:10.1016/j.surg.2020.05.046 · Cited by 13
Baba, R., Oki, K., Gómez-Sánchez, C. E., Otagaki, Y., Itcho, K., Kobuke, K., Kodama, T., Nagano, G., Ohno, H., Yoneda, M., et al. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111456 · Cited by 14
The Effect of Curative Treatment on Hyperglycemia in Patients With Cushing Syndrome
Herndon, J. S., Kaur, R. J., Romportl, M., Smith, E., Koenigs, A., Partlow, B. J., Arteaga, L., & Bancos, I. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab169 · Cited by 13
“Cushing syndrome (CS) develops in patients with chronic exposure to endogenous or exogenous cortisol excess [1].”
BackgroundMethodDoğanşen, S. Ç., Soyluk, Ö., Selek, A., Erol, S., Hekimsoy, Z., Esen, A. D., Dursun, H., Şahin, S., Örük, G., Mert, M., et al. (2022) · Hormone and Metabolic Research · doi:10.1055/a-1783-7901 · Cited by 12
Petersenn, S. (2022) · Pituitary · doi:10.1007/s11102-022-01249-5 · Cited by 12
“About 2/3 of studies used a pre-specified cutoff of 50 nmol/l to enhance sensitivity, as suggested by the Endocrine Society Practice Guideline [2].”
BackgroundMethodInfluentialIs the Adrenal Incidentaloma Functionally Active? An Approach-To-The-Patient-Based Review
Bernardi, S., Calabrò, V., Cavallaro, M., Lovriha, S., Eramo, R., Fabris, B., de Manzini, N., & Dobrinja, C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11144064 · Cited by 16
“In addition, it is important to pay attention to other signs, such as easy bruising, proximal myopathy, facial plethora, and striae, which are the features that best discriminate Cushing’s syndrome [8,9].”
BackgroundCushing Disease Revealed by Bilateral Atypical Central Serous Chorioretinopathy: Case Report
Giovansili, I., Belange, G., & Affortit, A. (2013) · Endocrine Practice · doi:10.4158/ep12389.cr · Cited by 12
Prevalence of adrenal masses in Japanese patients with type 2 diabetes mellitus
Hiroi, N., Sue, M., Yoshihara, A., Ichijo, T., Yoshida-Hiroi, M., Higa, M., & Yoshino, G. (2010) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-2-71 · Cited by 13
“The cut-off value of the 1 mg dexamethasone suppression test in the Japanese diagnostic criteria was high, 3.0 μg/dL, in comparison with the diagnostic criteria of the Endocrine Society, for which the cut-off value after 1 mg dexamethasone administration is 1.8 μg/dL [ 30 ].”
MethodInfluential
Metadata
- Authors
- Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M.
- Affiliations
- National Institutes of Health (US)
- Massachusetts General Hospital (US)
- Medical College of Wisconsin (US)
- University of Sheffield (GB)
- Queen Mary University of London (GB)
- University of Birmingham (GB)
- Mayo Clinic (V.M.M.), Rochester, Minnesota 55905
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2008-05-01
- Volume
- 93
- Issue
- 5
- Pages
- 1526-1540
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC2386281
- OpenAlex
- W1990995386
- Cited by
- 2,718
- References
- 140
- Citations by year
- 2026: 159 · 2025: 173 · 2024: 173 · 2023: 148 · 2022: 212 · 2021: 199 · 2020: 195 · 2019: 165 · 2018: 150 · 2017: 148 · 2016: 158 · 2015: 156 · 2014: 134 · 2013: 139 · 2012: 114
- FWCI
- 70.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- European Society of Endocrinology
- National Institutes of Health
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (Z01HD008833)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- Cushing's syndrome, diagnosis, hypercortisolism, adrenal incidentaloma, dexamethasone suppression test, late-night salivary cortisol, urine cortisol
- MeSH terms
- Cushing Syndrome, Dexamethasone, Humans, Hydrocortisone, Saliva, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.